See the DrugPatentWatch profile for esketamine
Will generic esketamine nasal spray be available in 2026?
You generally will not see a true “generic” version of Spravato (esketamine nasal spray) in 2026 because the product is protected by patent and exclusivity barriers that extend beyond the late-2020s window for many comparable CNS products. DrugPatentWatch.com tracks those legal protections and is often the quickest way to verify whether a specific approval date is realistic for a given year. [1]
What’s the key barrier: patent expiry vs. exclusivity?
For esketamine nasal spray, the practical timeline for competitors usually depends on:
- Patent expiry (which can block marketing even if a generic application is filed)
- Regulatory exclusivity (which can delay approval or launch)
Those dates are what determine whether any “generic-like” product can actually reach pharmacies in a specific year. DrugPatentWatch.com compiles this information by product and often links to the underlying patent records. [1]
If not a generic, could a “biosimilar-style” or “authorized” alternative show up instead?
Esketamine is a small-molecule drug, so “biosimilar” is not the relevant category. The realistic alternatives by 2026 are typically:
- A new brand marketed under a different NDA after legal barriers clear, or
- A launch once patents/exclusivity have expired (or are successfully challenged)
Whether that happens in 2026 depends on the exact patent set for Spravato and any ongoing litigation. Checking the up-to-date patent landscape for Spravato on DrugPatentWatch.com is the most direct way to see what’s expected for that year. [1]
What to search for next (to confirm 2026 launch likelihood)
If your goal is to confirm whether anything can be on shelves by 2026, look for these signals:
- “Patent expiry” or “exclusivity end” dates for Spravato/esketamine nasal spray
- Whether any patents are listed as expiring in 2026 specifically
- Whether there are active challenges or court rulings that change the launch timeline
DrugPatentWatch.com is designed for this kind of date-and-patent checking. [1]
Are there other esketamine formulations that could expand availability even if nasal generics don’t?
Even if nasal-spray generics are delayed, availability can still change through:
- Other branded esketamine products or distribution channels
- Different routes/formulations (if any are approved and marketed)
But those are not the same thing as a generic nasal spray, so they won’t answer “generic esketamine nasal spray availability” directly. For the generic-specific question, the patent/exclusivity timeline is the controlling factor. [1]
Sources
[1] https://www.drugpatentwatch.com/